BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
LATEST POSTS
- 1
A Manual for SUVs with Less Noteworthy Gas Mileage - 2Cheetos and Doritos to launch new versions without artificial dyes
- 3The most effective method to Alter Your Kona SUV for Greatest Solace and Comfort
- 4Nurturing Hacks: Astuteness from Experienced Mothers and Fathers
- 5Dental, Vision, and Hearing Inclusion in Senior Protection.
- A definitive Manual for Well known Fragrances
- Czech Republic's new premier: No money for Ukraine
- 10 Setting up camp Shelters That Offer Both Excellence and Isolation
- Emergent Cold LatAm opens state-of-the-art cold storage hub in Guadalajara
- When fake data is a good thing – how synthetic data trains AI to solve real problems
- They grew up with 'almond moms.' Now, they dread going home for the holidays.
- Pilot captures jaw-dropping northern lights show from 36,000 feet (photos)
- The Way to Monetary Health: Individual budget Change
- Illustrations Gained from a Crosscountry Excursion
